Allergy Associates of Utah is currently conducting clinical trials for patients who suffer from asthma and allergies. If you are interested in participating in a clinical research trial please contact our office (801) 263-8700 to see if you qualify.

Current Studies:

Stratos I: A 52-Week study for adolescents and adults 12 to 75 years old with persistent asthma.  The primary objective of the study is to evaluate the effect of tralokinumab 300 mg administered every 2 weeks compared with placebo on the annualised asthma exacerbation rate in adult and adolescent subjects with asthma that is inadequately controlled with inhaled corticosteroid plus long-acting ß2-agonist.

Chase Study: A 12-week study for children aged 6-11 years with asthma.  The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12 weeks.

TEVA 305 Study:  A 6-month study for adolescents and adults 12 years and up with persistent asthma. The primary objective of the study is to evaluate the long-term safety of fluticasone propionate inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation powder in 2 strengths when administered with the Teva MDPI device over 26 weeks in patients with persistent asthma.

TEVA 301 Study:  A 12-week study for adolescents and adults 12 years and up with persistent asthma. Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.

Prospero Study: A prospective observational study to evaluate predictors of clinical effectiveness in response to omalizumab (Xolair).

Lavolta II: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.

breakglass

Is uncontrolled ASTHMA a source of frustration in your life?

Are you unable to control your asthma with conventional asthma controller medications? Are your normal daily activities interrupted or can you no longer sleep soundly at night due to your asthma?

Although current asthma treatments do exist, many patients, like you, do not get effective relief from these treatments. More research is needed to develop new treatment options for patients who are unable to control their asthma with current medications.

Local doctors are now conducting two medical research studies, LAVOLTA I and LAVOLTA II, of an investigational asthma drug called lebrikizumab. They want to learn more about the safety and effectiveness of lebrikizumab when it is given to patients who are unable to control their asthma with conventional asthma controller medications.

Vestri Study: A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma.

About the VESTRI Study

The VESTRI Study is a worldwide clinical research study. About 6,200 children will participate in the VESTRI Study. The purpose of this clinical research study is to learn more about the safety of the asthma medications being researched.

Participants in the VESTRI Study will receive one of two asthma medications. There is no placebo (inactive substance, sometimes referred to as a sugar pill) and no blood draws (no needles) during this clinical research study.

Participation in the VESTRI Study will last about six months and participants will be asked to attend a minimum of five visits at a nearby study site.

Your child may qualify if they:

  • are 4 to 11 years of age
  • have had asthma for at least six months
  • have had asthma bad enough to see a doctor in the last 12 months

There are other study requirements that will determine who may participate in this clinical research study.

Study participants may receive study medication, study-related medical care and study procedures at no charge. Health insurance is not needed to participate.


Austri Study: A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 12,000 subjects 12 years old and older with persistent asthma.

 

About the AUSTRI Study

The AUSTRI Study is a worldwide clinical research study. About 12,000 people will participate in the AUSTRI Study. The purpose of this clinical research study is to learn more about the safety and effectiveness of the asthma medications being researched.

Participants in the AUSTRI Study will receive one of two asthma medications. There is no placebo (inactive substance, sometimes referred to as a sugar pill) and no blood draws (no needles) during this clinical research study.

Participation in the AUSTRI Study will last about 29 weeks and participants will be asked to attend a minimum of five visits at a nearby study site.

You or your child may qualify if they:

  • are 12 years of age or older
  • have had asthma for at least one year
  • are receiving asthma treatment
  • have had asthma bad enough to see a doctor in the last 12 months

There are other study requirements that will determine who may participate in this clinical research study.

Study participants may receive study medication, study-related medical care and study procedures at no charge. Health insurance is not needed to participate.

 

 

 

 

Share